PULM-001

**PULM-001** is a repurposed and reformulated version of dapsone, a small molecule drug with a well-established safety profile, developed by Canadian startup Pulmonem for treating acute respiratory distress syndrome (ARDS), particularly in COVID-19 patients. It acts as an **anti-inflammatory, immunomodulator, and antibacterial agent**, historically used for infectious diseases like malaria, lupus, HIV, and pneumocystis pneumonia. In a COVID-19 study, dapsone administration resulted in 0% mortality at ARDS onset versus 40% without, de-risking its Phase 3 program. Pulmonem has secured IND approvals from FDA and Health Canada for Phase 3 trials targeting early-stage COVID-19 to reduce lung inflammation, hospitalizations, ICU admissions, and death; it is affordable and administered orally.[1][3][4]